The AMALFI study looked at the possible benefits of screening people using a new Zio Patch monitor to detect atrial fibrillation, a common heart rhythm disorder. Half of the people in this study were sent the patch and half were not, so that we could compare the Zio Patch to the usual medical care people receive on the NHS. The patch was worn continuously for two weeks.

The study team monitored each participant's medical record for two and a half years to see what happened to them during this time and whether the screening made a difference. Read the results of the trial in our news item and watch our animation. 

We will be undertaking further research to find out whether screening in this way helps to prevent strokes and whether it is cost-effective.

The study was led by Professor Louise Bowman and Professor Barbara Casadei and involves cardiology and General Practice specialists as well as partnership work with many other local doctors, nurses and healthcare professionals.

AMALFI was designed by the University of Oxford, who run the study independently of any funders. Funding for the trial was provided by the National Institute for Health and Care Research Oxford Biomedical Research Centre and the British Heart Foundation. iRhythm Technologies (San Francisco, CA) supported the study by providing the Zio long-term continuous monitoring service (Zio® XT monitoring devices, ECG analysis and cardiac technician data review) at no charge.